PT  - JOURNAL ARTICLE
AU  - Mykola Ostrovskyy
AU  - Mariana Kulynych-Miskiv
AU  - Iryna Savelikhina
AU  - Oleksandr Varunkiv
TI  - Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD
DP  - 2014 Sep 01
TA  - European Respiratory Journal
PG  - P563
VI  - 44
IP  - Suppl 58
4099  - http://erj.ersjournals.com/content/44/Suppl_58/P563.short
4100  - http://erj.ersjournals.com/content/44/Suppl_58/P563.full
SO  - Eur Respir J2014 Sep 01; 44
AB  - OBJECTIVE: We investigated the effects of treatment with the long-acting muscarinicreceptor antagonist tiotropium on collagen-IV level in bronchoalveolar fluid before and during the treatment in patient with COPD II stages.METHODS:The type IV collagen was tested using commercially available ELISA kits, in accordance with the manufacturer's recommendations (Collagen IV ELISA®, Echelon Biosciences Inc, Salt Lake City, EUA).The content of type IV collagen was investigated in bronchoalveolar fluid after bronchoscopy in 49 patients with stage 2 COPD before and after treatment. The severity of COPD was classified by the FEV1 % predicted, according to the guidelines established by the GOLD.RESULTS: The results of our research showed that in patients with COPD on early stages (2nd stage) was accompanied by increased content of collagen type IV in bronchoalveolar fluid in 6.19 times compared with healthy. We found further positive trends - reduction of type IV collagen on 79.4% with using tiotropium bromide within 2 months. The level of type IV collagen in bronchoalveolar fluid dropped in 2.23 times (p<0.05) compared with the level before treatment.Finally, we identified practically complete normalization of type IV collagen levels in bronchoalveolar fluid only during 6-month of tiotropium bromide admission in patients with stage 2 COPD. This rate was higher only at 29.8% (p <0,05) comparing with healthy.CONCLUSIONS: The reduction of type IV collagen content in bronchoalveolar fluid under tiotropium bromide treatment during 6 month is a clear evidence of inhibiting effects of tiotropium bromide on the processes of neocollagenesis.